Prolia doesn’t have a traditional generic, but several biosimilar versions have been approved by the FDA starting in 2025. The first of these became available for purchase in mid-2025, giving patients a lower-cost alternative to the brand-name drug for the first time since Prolia launched.
Why Prolia Has Biosimilars, Not Generics
Prolia (denosumab) is a biologic medication, not a conventional pill synthesized from chemicals. It’s a lab-made antibody produced by living cells, which makes it far more complex than a typical small-molecule drug like ibuprofen or metformin. That complexity matters because it changes how copies of the drug are made and regulated.
Generic drugs contain the exact same active ingredient as the brand-name version. Manufacturers prove they’re bioequivalent, and the FDA approves them through a relatively straightforward process. Biologics don’t work that way. Because they’re grown in living systems like yeast or animal cells, tiny natural variations occur between production batches. No two manufacturers can produce a perfectly identical copy. Instead, they produce what the FDA calls a “biosimilar,” a version that is highly similar to the original with no clinically meaningful differences in safety or effectiveness.
For practical purposes, a biosimilar does the same thing as the original. The distinction is regulatory, not functional. You can think of it as the biologic equivalent of a generic.
FDA-Approved Prolia Biosimilars
The FDA has approved multiple denosumab biosimilars so far. The first, Jubbonti, received approval as an interchangeable biosimilar to Prolia, meaning pharmacists can substitute it for the brand-name product without needing a new prescription from your doctor (depending on your state’s pharmacy laws). Several others followed in rapid succession:
- Jubbonti (denosumab-bbdz): first interchangeable biosimilar approved for Prolia
- Aukelso and Bosaya (denosumab-kyqq): approved September 2025
- Enoby and Xtrenbo (denosumab-qbde): approved September 2025
- Osvyrti and Jubereq (denosumab-desu): approved October 2025
- Boncresa and Oziltus (denosumab-mobz): approved December 2025
- Ponlimsi (denosumab-adet): approved March 2026
FDA approval doesn’t always mean a product is on pharmacy shelves yet. Patent settlements between Amgen (the maker of Prolia) and biosimilar manufacturers have controlled the actual launch dates. For example, Sandoz reached a settlement allowing its biosimilar products to launch on May 31, 2025, after a court ruled that Amgen’s patents were valid and had been infringed.
What Biosimilars Are Approved to Treat
The approved biosimilars cover the same conditions as Prolia itself. That includes osteoporosis in postmenopausal women at high fracture risk, bone loss in men with osteoporosis, glucocorticoid-induced osteoporosis in both men and women, and bone loss in men receiving hormone therapy for prostate cancer or women on aromatase inhibitor therapy for breast cancer. If you currently take Prolia for any of these reasons, a biosimilar is approved for your indication.
How Prolia Works
Prolia and its biosimilars work by blocking a protein that tells your body to break down bone. Normally, your bones are in a constant cycle of being broken down and rebuilt. In osteoporosis, the breakdown side outpaces the rebuilding side. Denosumab targets the signal that activates the cells responsible for dissolving bone, slowing that process down and allowing your bones to retain more density. It’s given as an injection under the skin once every six months.
What This Means for Cost
Brand-name Prolia carries a list price of roughly $1,700 per injection, which translates to about $3,400 per year for the standard twice-yearly dosing schedule. Biosimilars are expected to cost less, though specific pricing varies by manufacturer and insurer. Historically, biosimilar competition in other drug categories has driven prices down meaningfully, and the number of approved denosumab biosimilars suggests competitive pressure will build over time.
Your out-of-pocket cost depends heavily on your insurance plan. If your biosimilar has interchangeable status (as Jubbonti does), your pharmacist may be able to fill a Prolia prescription with the biosimilar automatically, potentially at a lower copay. It’s worth asking your pharmacist or insurance company whether a biosimilar is covered on your plan and what the cost difference looks like for your specific situation.
Switching From Prolia to a Biosimilar
Because interchangeable biosimilars must demonstrate no clinically meaningful differences from the original, switching is considered safe. The FDA’s interchangeability designation specifically means the product can be expected to produce the same clinical result as Prolia in any given patient. You should not experience a difference in how well the medication works or in side effects.
One important note: denosumab (whether brand or biosimilar) should not be stopped abruptly. Discontinuing treatment can lead to a rapid loss of bone density and an increased risk of spine fractures. If you’re considering any change to your treatment, including switching products, that conversation should happen with your prescriber to ensure there’s no gap in your dosing schedule.